Hypoglossal Nerve Stimulator Outcomes for Patients Outside the U.S. FDA Recommendations

Objectives The hypoglossal nerve stimulator (HGNS) is currently approved for the treatment of obstructive sleep apnea (OSA) in patients with an apnea‐hypopnea index (AHI) of >15 to ≤65 events/hour, and a central apnea index (CAI) 50% and AHI

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Laryngoscope 2020-04, Vol.130 (4), p.866-872
Hauptverfasser:	Sarber, Kathleen M., Chang, Katherine W., Ishman, Stacey L., Epperson, Madison V., Dhanda Patil, Reena
Format:	Artikel
Sprache:	eng
Schlagworte:	Body mass index Food and Drug Administration hypoglossal nerve stimulator neurostimulation Obstructive sleep apnea Sleep apnea surgery for obstructive sleep apnea Surgical outcomes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives The hypoglossal nerve stimulator (HGNS) is currently approved for the treatment of obstructive sleep apnea (OSA) in patients with an apnea‐hypopnea index (AHI) of >15 to ≤65 events/hour, and a central apnea index (CAI) 50% and AHI
ISSN:	0023-852X 1531-4995
DOI:	10.1002/lary.28175